On Jan. 11, 2021, Baxter announced an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavaxﾒ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-Mﾙ adjuvant. The agreement was expected to advance commercial-scale manufacturing essential for the vaccineﾒs production and distribution in the UK and European markets.